111PCERITINIB TREATMENT OF PATIENTS (PTS) WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES: ASCEND-1 TRIAL EXPERIENCE